Glucagon-like peptide-1 (GLP-1) agonists are a class of medications frequently used to treat type 2 diabetes mellitus (T2DM) and obesity.[1] This class of medications assists in lowering blood sugar levels and promotes weight loss. In addition to treating diabetics, these medications are also used to treat obesity in diabetics as well as non-diabetics.   GLP-1 drugs…

Open claims and closed claims data serve as vital tools for comprehending patients’ progress and engagements throughout their healthcare voyage. However, which data type proves most advantageous and under what circumstances? Whether the need is to assess the cost-effectiveness of a recently introduced medication or streamline clinical trial recruitment, both open claims data and closed…

As treatment options for patients are constantly evolving, staying ahead of the curve is critical for life science companies and physicians. But with so many options in the market, how can companies gain a competitive advantage with prescribers? By leveraging real-time data that offers unprecedented insights into physician behavior and patient outcomes. PurpleLab®, a healthcare…

Healthcare today is evolving into precision medicine, or what the FDA refers to as personalized medicine.  To stay competitive in the constantly shifting healthcare landscape, organizations across the healthcare ecosystem must embrace this targeted approach and leverage the tools needed to make safe decisions for their patients or populations. By unlocking insights provided from advanced…

The Skinny on Weight loss Drugs This podcast was created in collaboration with the Pharmacy Podcast Network. PurpleLab’s dataset from October 2022 – October 2023 shows that 2.8M people had been prescribed and dispensed a semaglutide drug.  PurpelLab’s database shows who really is getting access to the drugs by looking into:  States with most prescriptions (and zoom…

Standardized pricing imputes proxy costs that provide parity across data sources to determine healthcare costs. This allows you to facilitate nationwide studies of healthcare utilization and comparative analyses using the adjusted price, geographically adjusted price, and line of business adjusted price for services. Life Sciences Download Let’s Talk! Previous Next

PurpleLab was selected to present a poster at PMSA 2024 on imputing SDOH information on pharmacy claims. This study was centered around prescription fill rates of Semaglutides in the adolescent population. In December of 2022, the FDA approved adolescents BMI at or above the 95th percentile eligible for a Semaglutide prescription. PurpleLab used a combination…

A large CRO has incorporated PurpleLab data directly into their workflow to support all therapeutic areas and phases of clinical trial work from RWE and pre-award through phase IV and beyond including market access and HEOR work. This strategy has been incorporated for all of their clients.  “The data and services provided by PurpleLab have…

Cookie-less Marketing for Pharmaceuticals and the Role of Real-World Data (RWD) Life Sciences Pharmaceutical marketing is undergoing a significant transformation as third-party cookies become obsolete. To navigate this shift, pharmaceutical companies must embrace cookie-less marketing strategies, leveraging real-world data throughout the advertising campaign lifecycle.  In this whitepaper, we explore: The impact of cookie-less marketing on…